Keyphrases
Brain Inflammation
100%
Neurocysticercosis
100%
Seizure
36%
Inflammatory Response
27%
Natural Host
18%
Specific Intent
18%
Oncosphere
18%
Metacestode
18%
BBB Breakdown
18%
Epilepsy
18%
Taenia Solium
18%
Brain Tissue
18%
Low-resource Countries
9%
Ventricle
9%
BBB Dysfunction
9%
Epidemiologic Studies
9%
FDA-approved Drugs
9%
Epileptogenesis
9%
Risk Factors
9%
Edema
9%
Morphological Characteristics
9%
H Component
9%
Endemic Region
9%
Extraparenchymal
9%
Recurrent Seizures
9%
Novel Animal Model
9%
Rat Brain
9%
Epileptic Seizure
9%
Active Epilepsy
9%
Brain Cyst
9%
Pork Tapeworm
9%
Principal Investigator
9%
Age of Infection
9%
Tumor Necrosis Factor-α
9%
Rat Model
9%
Peru
9%
Public Health Risk
9%
Larval Stages
9%
Human Infestation
9%
BBB Integrity
9%
Antiparasitic Treatment
9%
Meninges
9%
Program Directors
9%
Response Activation
9%
Inflammatory Pathways
9%
Central Nervous System Involvement
9%
Anti-inflammatory Therapy
9%
Clinical Manifestations
9%
Inflammation Diseases
9%
Astroglial Activation
9%
Cysticercosis
9%
Astroglial
9%
Glial Activation
9%
Medicine and Dentistry
Encephalitis
100%
Neurocysticercosis
100%
Epileptic Seizure
54%
Blood Brain Barrier
36%
Serositis
27%
Anti-Inflammatory Drug
18%
Taenia Solium
18%
Natural Host
18%
Oncosphere
18%
Metacestode
18%
Brain Tissue
18%
Disease
9%
Brain Cyst
9%
Morphology
9%
Cysticercosis
9%
Ventricle of Heart
9%
Epileptogenesis
9%
Antiparasitic Therapy
9%
Meninx
9%
Infection
9%
Larval Stage
9%
Central Nervous System
9%
Cohort Effect
9%
Public Health
9%
Tumor Necrosis Factor
9%
Edema
9%
Program Director
9%
Pharmacology, Toxicology and Pharmaceutical Science
Encephalitis
100%
Neurocysticercosis
100%
Inflammation
36%
Metacestode
18%
Taenia Solium
18%
Natural Host
18%
Anti-Inflammatory Drug
18%
Oncosphere
18%
Disease
9%
Infection
9%
Tumor Necrosis Factor
9%
Rat Model
9%
Epidemiology
9%
Edema
9%
Epileptogenesis
9%
Brain Cyst
9%
Seizure
9%
Antiparasitic Agent
9%
Cysticercosis
9%